Citius Oncology

Citius Oncology Enterprise Value

The Enterprise Value (EV) of Citius Oncology (CTOR) as of Nov 22, 2026 is 60.86 M USD. In the previous year, Enterprise Value (EV) was 64.78 M USD — a change of -6.06% (lower).

Enterprise Value

60.86 MUSD

YoY

-6.06%

Last updated:

Enterprise Value (EV) of Citius Oncology is 2025 60.86 M USD. Enterprise Value (EV) of Citius Oncology was 2024 64.78 M USD. It decreases by -6.06% lower compared to the previous year.

The Citius Oncology Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2021
60.98 M USD
Jan 1, 2022
60.98 M USD
Jan 1, 2023
60.98 M USD
Jan 1, 2024
64.78 M USD
Jan 1, 2025
60.86 M USD
The Citius Oncology Enterprise Value history
YEAREnterprise ValueYoY
60.86 MUSD-6.06%
64.78 MUSD+6.23%
60.98 MUSD0.00%
60.98 MUSD0.00%
60.98 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Citius Oncology stock

Enterprise Value (EV) of Citius Oncology is 60.86 M USD in 2025.

Enterprise Value (EV) of Citius Oncology changed from 64.78 M USD to 60.86 M USD, representing a -6.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Citius Oncology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Citius Oncology

All Key Metrics — Citius Oncology